ROR1 has garnered significant attention as a therapeutic target in oncology due to its critical involvement in cancer malignancy.
Several biologics targeting ROR1 have advanced to clinical trials, but the development of selective small-molecule inhibitors remains limited.
In our previous work, we identified the indole-based
